Antibody Development
MONOCLONAL ANTIBODIES
At OBT, we collaborate with world leaders in the field to develop antibodies specific to the unique cancer targets identified by us. The monoclonal antibodies incorporated into our antibody-drug conjugates (ADCs) are engineered to bind specifically to highly expressed proteins on the cancer cell membranes and selected specifically for optimum performance in delivering toxins to cancer cells.
BISPECIFIC ANTIBODIES
A bispecific antibody is one that can bind simultaneously to two different antigens. With our unique matrix of cancer-immune cell target combinations, OBT is uniquely positioned to develop bispecific molecules to enhance recruitment and activation of immune cells for the targeted killing of cancer cells.
At OBT, we collaborate with world leaders in the field to develop antibodies specific to the unique cancer targets identified by us. The monoclonal antibodies incorporated into our antibody-drug conjugates (ADCs) are engineered to bind specifically to highly expressed proteins on the cancer cell membranes and selected specifically for optimum performance in delivering toxins to cancer cells.
BISPECIFIC ANTIBODIES
A bispecific antibody is one that can bind simultaneously to two different antigens. With our unique matrix of cancer-immune cell target combinations, OBT is uniquely positioned to develop bispecific molecules to enhance recruitment and activation of immune cells for the targeted killing of cancer cells.
Therapies stemming from the combination of OBT's IO matrix of target combinations and bispecific antibodies harness the body's immune system to kill cancer cells. This results in a highly specific IO response in the absence of the systemic side effects encountered with conventional chemotherapies.
